Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Replimune
Biotech
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
Replimune’s fortunes flipped today after an advisory committee voted 10 to 3 in favor of oncolytic virus RP1's effectiveness.
Darren Incorvaia
Jul 30, 2026 6:20pm
Shedding 60% of workforce, Replimune vows to continue operations
Apr 21, 2026 2:15am
Replimune to lay off staff after 'disappointing' second rejection
Apr 10, 2026 1:56pm
Replimune's stock spikes 100% on FDA acceptance of resubmission
Oct 20, 2025 5:33pm
FDA rejects another ultrarare disease prospect
Sep 8, 2025 10:59am
FDA plans real-time release of drug rejection letters
Sep 4, 2025 1:45pm
